Bristol-Myers Squibb: Cobenfy's Strong Launch And 2025 Growth Outlook

Group 1 - Cobenfy's FDA approval is expected to significantly contribute to Bristol-Myers Squibb's growth starting in 2025 [1] - The company reported its Q4 2024 financial and business results, indicating a focus on the potential of novel treatments [1] - The analyst has over 20 years of experience in research and development of Cell & Gene Therapies, emphasizing the importance of these therapies in addressing clinical needs [1] Group 2 - The analyst expresses a beneficial long position in the shares of Bristol-Myers Squibb and AbbVie, indicating confidence in their future performance [2] - The article reflects the analyst's independent opinions and is not influenced by any compensation from the companies mentioned [2]